Intelligence Feed event · Equity · 2026-09-19

    Twist Bioscience Rallies 31% on Eli Lilly AI Drug Discovery Collaboration

    Question

    Twist Bioscience Rallies 31% on Eli Lilly AI Drug Discovery Collaboration

    Direct answer

    Twist Bioscience (TWST) shares gained 31% following the announcement of a strategic collaboration with Eli Lilly (LLY) around the Lilly TuneLab AI-assisted drug discovery platform. Under the partnership terms, Twist provides antibody characterization services leveraging its proprietary AbLab data model, opening a direct revenue stream linked to pharma discovery budgets.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-19
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Twist Bioscience Rallies 31% on Eli Lilly AI Drug Discovery Collaboration”, revision 1, evidence through 2026-09-19. https://marketontology.com/market-events/2026-09-19/twist-bioscience-rallies-31-on-eli-lilly-ai-drug-discovery-collaboration-a8e855

    EQUITY
    Twist Bioscience Rallies 31% on Eli Lilly AI Drug Discovery Collaboration
    Twist Bioscience (TWST) shares gained 31% following the announcement of a strategic collaboration with Eli Lilly (LLY) around the Lilly TuneLab AI-assisted drug discovery platform. Under the partnership terms, Twist provides antibody characterization services leveraging its proprietary AbLab data model, opening a direct revenue stream linked to pharma discovery budgets.
    TWSTLLY
    Impact
    68
    SEP 19
    SIG
    85%
    TWSTLLY
    Twist Bioscience Rallies 31% on Eli Lilly AI Drug Discovery Collaboration
    Twist Bioscience (TWST) shares gained 31% following the announcement of a strategic collaboration with Eli Lilly (LLY) around the Lilly TuneLab AI-assisted drug discovery platform. Under the partnership terms, Twist provides antibody characterization services leveraging its proprietary AbLab data model, opening a direct revenue stream linked to pharma discovery budgets.
    → Biotech data partnerships with major pharmaceutical sponsors deliver upfront service revenues and commercial validation for computational biology platforms.
    Impact
    Twist Bioscience (TWST) shares gained 31% following the announcement of a strategic collaboration with Eli Lilly (LLY) around the Lilly TuneLab AI-assisted drug discovery platform. Under the partnership terms, Twist provides antibody characterization services leveraging its proprietary AbLab data model, opening a direct revenue stream linked to pharma discovery budgets.
    Affected
    TWSTLLY
    Transmission
    Biotech data partnerships with major pharmaceutical sponsors deliver upfront service revenues and commercial validation for computational biology platforms.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    TWSTbiopharma service revenue expansion and validationUp1-5dTWST shares surged over 31% following the Eli Lilly TuneLab partnership.
    LLYpipeline R&D efficiency gains via AI antibody screeningWatch1-3mLilly integrated Twist's antibody data into its TuneLab initiative.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month